Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for RHHBY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RHHBY and 80,000+ other tickers.
See exactly how RHHBY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RHHBY and 80,000+ other tickers.
Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic…
WORCESTER, Mass., July 15, 2026 /PRNewswire/ -- The Hanover Insurance Group, Inc., (NYSE: THG), a leading property and casualty insurance company, announced today that John "Jack" C.
Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.
Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.
RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.
Experimental drug, divarasib, showed meaningful improvements in both patients' overall survival and the time they survived without the disease worsening.